T-box transcription factor, TBX1, is the major candidate gene for 22q11.2 deletion syndrome (DiGeorge/ Velocardio-facial syndrome) characterized by facial defects, thymus hypoplasia, cardiovascular anomalies and cleft palates. Here, we report that the loss of Tbx1 in mouse (Tbx1 2/2 ) results in skeletal abnormalities similar to those of cleidocranial dysplasia (CCD) in humans, which is an autosomal-dominant skeletal disease caused by mutations in RUNX2. Tbx1 2/2 mice display short stature, absence of hyoid bone, failed closure of fontanelle, bifid xiphoid process and hypoplasia of clavicle and zygomatic arch. A cell-type-specific deletion of Tbx1 in osteochondro-progenitor (Tbx1 OPKO ) or mesodermal (Tbx1 MKO ) lineage partially recapitulates the Tbx1 2/2 bone phenotypes. Although Tbx1 expression has not been previously reported in neural crest, inactivation of Tbx1 in the neural crest lineage (Tbx1 NCKO ) leads to an absence of the body of hyoid bone and postnatal lethality, indicating an unanticipated role of Tbx1 in neural crest development. Indeed, Tbx1 is expressed in the neural crest-derived hyoid bone primordium, in addition to mesoderm-derived osteochondral progenitors. Ablation of Tbx1 affected Runx2 expression in calvarial bones and overexpression of Tbx1 induced Runx2 expression in vitro. Taken together, our current studies reveal that Tbx1 is required for mesoderm-and neural crest-derived osteoblast differentiation and normal skeletal development. TBX1 mutation could lead to CCD-like bone phenotypes in human.
INTRODUCTION
Numerous birth defects are due to improper development of neural crest and are comprised at least a third of all birth defects in humans (1) . The 22q11.2 deletion syndrome (DiGeorge/ Velo-cardio-facial syndrome) is the most frequent chromosomal micro-deletion syndrome in humans and is characterized by a series of phenotypic abnormalities, including cardiac defects, abnormal faces (brachycephaly, micrognathia, hypertelorism, small low-set ears), cleft palate, thymic hypoplasia and hypocalcemia (2, 3) . Although the clinical features are highly variable and affect many organs, structures primarily affected in 22q11.2 deletion syndrome are derivatives of the branchial arches, suggesting that defects in branchial arch development cause most features of this syndrome (4, 5) .
Mice harboring a homozygous deletion of Tbx1, a member of T-box transcription factors have most features of 22q11.2 deletion syndrome, including micrognathia, cleft palate, skeletal muscle hypotonia and ear abnormalities, further supporting the role for Tbx1 in this syndrome (6 -9) . It has been postulated that 22q11.2 deletion syndrome could be accounted for by a disturbance of migration or differentiation of the cranial and cervical neural crest into the branchial arches, pouches and outflow tract (10, 11) . Although Tbx1 expression has not been reported in the neural crest, Tbx1 was shown to be expressed in the branchial endoderm and mesoderm, and broadly in the head mesenchyme, suggesting its role in neural crest development (10, 12) .
During embryogenesis, bones develop either by intramembranous or endochondral ossification. Membranous bones are derived from osteoprogenitor cells, which differentiate directly into osteoblasts without a cartilaginous template, whereas endochondral bones use cartilaginous templates. Membranous bones account for cranial bones, a part of the clavicle and mandible. In mammals, both cranial neural crest-and mesoderm-derived cells contribute to the development of the skull. Frontal bones are derived from neural crest, whereas parietal bones are derived from mesoderm in the mouse (11) . Several transcription factors that control patterning and maturation of the intramembranous ossification have been identified. Runx2, a member of the Runt family of transcription factors, is necessary for osteoblast differentiation and chondrocyte hypertrophy (13, 14) . Runx2 2/2 mice show the complete loss of intramembranous ossification. Runx2 +/2 mice display short stature, failed closure of fontanelles, hypoplasia of clavicle, zygomatic arch and hyoid bone (13, 15) . These specific skeletal abnormalities are characteristic of the cleidocranial dysplasia (CCD) in humans, which is an autosomaldominant skeletal disease caused by mutations in RUNX2 (OMIM, #119600).
Here, we demonstrate that ablation of Tbx1 in osteoprogenitor cells impairs bone development and subsequent bone ossification. Tbx1 2/2 mice show specific bone defects that recapitulate the skeletal phenotype of the Runx2 +/2 mice and those of CCD. Ablation of Tbx1 in the neural crest results in the absence of the body of hyoid bone, revealing its unexpected role in the development of neural crest within the second branchial arch.
RESULTS

Tbx1
2/2 mice display skeletal abnormalities
Since Tbx1 2/2 mice exhibit craniofacial defects (6, 8, (16) (17) (18) , we analyzed Tbx1 2/2 mice for skeletal abnormalities at postnatal day (P) 1 in detail. As previously reported, alizarin red and alcian blue staining revealed that hyoid bone was completely absent and thyroid cartilage was reduced and fragmented in all Tbx1 2/2 mice (n ¼ 17) ( Fig. 1Ah and i) . Abnormalities in the zygomatic arch and temporal bones were also observed in all Tbx1 2/2 mice analyzed (Fig. 1Aj ). There was also delayed ossification of the cranial bones resulting in open anterior and posterior fontanelles, as well as wide cranial sutures (Fig. 1Ak) . The parietal, interparietal and occipital bones were also reduced in size ( Fig. 1Ak and Supplementary Material, Fig. S1A and Table S1 ). Consistent with the previous report (6, 19, 20) , the mandibles of Tbx1 2/2 mice were smaller compared with littermate controls (Fig. 1Al) . The mice also showed a wider-thannormal xiphoid process with two well-separated ossification centers (Fig. 1Bd) and the atlas and axis in the vertebral column lacked the anterior arch ( Fig. 1Be and f) . The skeletal components in the middle ear, such as incus and stapes, were also malformed (Supplementary Material, Fig. S2A and Table S1 ), as previously reported (18) . Other notable skeletal defects in Tbx1 2/2 mice were hypoplasia of the clavicle (Fig. 1Bb) , where the combination of intramembranous and endochondral bone formation is observed (21) .
Interestingly, these bone phenotypes were strikingly similar to that of CCD (OMIM, #119600), which is an autosomaldominant skeletal disease that results from mutations in the osteogenic master transcriptional factor RUNX2. The Tbx1 Fig. S3 ). Since the endochondral bones of the basal skull were defective in Tbx1 2/2 mice (8,17), it indicated that endochondral cartilages were also sensitive to the level of Tbx1. By comparison, we observed no abnormalities in Tbx1 +/2 embryos (Supplementary Material, Table S1 and Fig. S4 ). Taken together, these findings suggested that Tbx1 played an essential role in bone development.
Conditional deletion analysis of Tbx1 in the osteochondro-progenitors and mesodermal cells
To further investigate the potential involvement of Tbx1 in bone development, we used the conditional gene silencing approach to specifically inactivate Tbx1 in the osteoprogenitor lineages. We deleted Tbx1 from the early precursors of all cell types of the developing bone by using the Twist2-Cre mice (22) (23) (24) . A Tbx1 knockout allele (Tbx1 KO ) was incorporated to increase the overall frequency of targeted alleles. Tbx1 loxP/KO ; Twist2-Cre (hereafter Tbx1 OPKO ) mice were born alive with the expected Mendelian frequency ( 25%). The stomachs of Tbx1 OPKO mice (eight of eight at P1) contained no milk (Fig. 2Ah) , and they died within 24 h of birth, for unknown reasons. Analysis of the skeletons of Tbx1 OPKO mice also revealed a lack of subperiosteal bone formation within the hyoid bone and a fusion between the hyoid bone and thyroid cartilage (Fig. 2Aj -l ). There were no significant abnormalities in open anterior or posterior fontanelles, as well as cranial sutures (Fig. 2Am) ; however, the width of parietal bones was significantly reduced in size in Tbx1 OPKO mice (P ¼ 0.0035, Supplementary Material, Table S1 and Fig. S1B ). No significant abnormalities were found in the zygomatic arch, temporal bone and mandible in Tbx1 OPKO mice ( Fig. 2An and Supplementary Material, Table S1 ). The phenotypes of the clavicle and xiphoid process were similar to those seen in Tbx1 2/2 mice ( Fig. 2Ba and c ). In the vertebral column, the anterior arch of the atlas and axis was hypoplastic ( Fig. 2Bd and e) .
Since Tbx1 OPKO showed a similar overall but milder cranial phenotype when compared with that of Tbx1 2/2 mice (Figs 1 and 2), we speculated that this might be due to the limited expression pattern of Twist2-Cre during skull development. To ascertain whether Twist2-Cre is expressed in the developing skull, we performed lineage-tracing experiments to examine the contribution of the Twist2-Cre using Rosa26 reporter (R26R) mice (25) . LacZ-positive regions were widely detected in the frontal bones, parietal bones and the interparietal bone at P1 (Supplementary Material, Fig. S5 ), suggesting that Twist2 was expressed in the neural crest-and mesoderm-derived calvarial primordium.
The Twist2-Cre was generated by knocking in the Cre recombinase into the Twist2 locus and these mice were heterozygous for a Twist2 allele. In addition, Twist2 was shown to inhibit osteogenesis in vivo and a Twist2 null background rescued the clavicle phenotype in Runx2 +/2 mice (23 Table S2 and Fig. S6 ). Therefore, it was unlikely that Twist2 haplosufficiency suppressed or rescued the calvarial phenotypes in Tbx1 OPKO . Rather, the milder phenotype in Tbx1 OPKO compared with Tbx1 2/2 was possibly due to insufficient or relatively late activation of Cre-induced recombination of the Tbx1-floxed allele in osteochondral progenitors.
We next used the Mesp1-Cre, which was expressed in the early mesoderm, to examine the contribution of Tbx1 in bone development (26, 27) . Tbx1 loxP/KO ; Mesp1-Cre (hereafter Tbx1 MKO ) mutants showed brachycephaly, microcephaly and small low-set ears, recapitulating the Tbx1 2/2 facial phenotype ( Fig. 2Cf -h ). Skeletal staining revealed that hyoid bone and thyroid cartilage were reduced in all Tbx1
MKO mutants (n ¼ 3) at E18.5 (Fig. 2Ci) . There was also delayed ossification of the cranial bones resulting in open anterior and posterior fontanelles, as well as wide cranial sutures (Fig. 2Cj) . The parietal, interparietal and supraoccipital bones were reduced in size in Tbx1 MKO mice (Supplementary Material, Table S1 and Fig. S1C ). When we examined the contribution of the Mesp1-Cre to parietal bone development using R26R mice, the mesoderm-derived bones were reduced in size in all Tbx1
MKO mutants (n ¼ 3) at E16.5 (Fig. 2Eb) . The mutant mice also showed a hypoplastic clavicle, and wider-than-normal xiphoid process with two wellseparated ossification centers and the atlas in the vertebral column lacked the anterior arch at E18.5 ( Fig. 2D and Supplementary Material, Table S1 ). These findings clearly indicate that the primary defect in Tbx1 OPKO and Tbx1 MKO mice is in the control of the osteoprogenitor development in subsets of bones.
Inactivation of Tbx1 in the neural crest results in the absence of hyoid bone Hyoid bone and thyroid cartilages are derivatives of the second and more posterior branchial arches, respectively, which are populated by neural crest cells. In Tbx1 2/2 mice, abnormalities were observed in several components of neural crest-derivatives, in addition to mesoderm-derived membranous bones. The expression of Tbx1 was not previously reported in the neural crest. To test whether Tbx1 is directly required for the neural crest-derived craniofacial development, we deleted Tbx1 specifically in the neural crest cells by using Wnt1-Cre (28, 29) . Tbx1 loxP/KO ; Wnt1-Cre (hereafter Tbx1 NCKO ) mice died within 24 h of birth, although the cause of lethality remains unknown. Bone and cartilage staining of skeletons of Tbx1 NCKO mice (seven of seven at P1) highlighted a lack of subperiosteal bone formation within the hyoid bone and a fusion between a hyoid bone and thyroid cartilage ( Fig. 3Ai and j) . In the Tbx1 NCKO mice, the malleus showed delayed ossification (five of six at P1) compared with the control mice ( Fig. 3Cb and Supplementary Material, Table S1 ). However, other cranial neural crestderived bones, such as frontal bones, temporal bones, mandibles, OPKO (h) at P1. The Tbx1 OPKO mutant has an empty stomach (an arrow in h), whereas the control littermate has milk in the stomach (an arrow in a). (b-g and i -n) Alizarin red and alcian blue staining of control (b-g) and Tbx1
OPKO bones (i -n) of the lateral view of head (b and i), hyoid bone (c-e and j -l), skull (f and m) and mandible (g and n). The hyoid bone (hb) of the Tbx1 OPKO fails to undergo ossification (j -l) and fuses to the thyroid cartilage (an arrow in l). No difference between control and Tbx1 OPKO cranial sutures (f and m) and mandible (g and n). hb, hyoid bone, with lesser (lh) and greater (gh) horns; tc, thyroid cartilage; fb, frontal bone; pb, parietal bone; ip, interparietal bone. tympanic ring, stapes and gonial bones, were all normal in Tbx1 NCKO mice (Fig. 3Ak , l, C, and Supplementary Material, Table S1 ).
Tbx1 is expressed in the epithelium of facial process and oral epithelium (8, 30, 31) . To rule out the contribution of Tbx1 in the epithelial linage in craniofacial bone development, we crossed mice with the Tbx1 conditional alleles to the KRT14-Cre mice (32) . Bone staining of the Tbx1 loxP/KO ; KRT14-Cre mice (11 of 11 at P1) showed no bone phenotypes (Supplementary Material, Table S1 and Fig. S7 ), except for short palatal shelves of maxilla (8) , suggesting that Tbx1 expression in the epithelial layer did not affect the development of most of adjacent bones. These results clearly establish that Tbx1 is necessary for the development of neural crest cells in the branchial arch, especially in hyoid bone, whereas Tbx1 is not directly required in other neural crestderived bones.
Tbx1 is necessary for hyoid bone morphogenesis
Given the common and novel bone phenotype of the Tbx1 OPKO and Tbx1 NCKO mice, we focused the histological analysis on the developing hyoid bone using an allelic series of Tbx1 mutants. At E18.5, Safranin O staining of the wild-type embryo showed that hyoid bone was present rostral to the thyroid cartilage and contained numerous hypertrophic chondrocytes (Fig. 4Aa) . On the other hand, hyoid bone was completely absent and thyroid cartilage was hypoplastic in Tbx1 2/2 embryos (Fig. 4Ad) . The hyoid bone was aplastic, since the primordium of hyoid bone was not observed at E14.5 ( Fig. 4Ae and f) . In Tbx1 OPKO embryos, hyoid bone was present but was lacking hypertrophic chondrocytes and it fused to the thyroid cartilage ( Fig. 4Bc and d) .
Tbx1
NCKO embryos showed the similar hyoid bone phenotype as the Tbx1 OPKO embryos (Fig. 4Cd and e) and the defect was already present at E16.5 (Fig. 4Cf) .
Tbx1 NCKO mice showed the skeletal phenotype in the neural crest-derived hyoid bone (Figs 3Ai and j and 4C), although Tbx1 expression was not previously reported in the neural crest. To determine whether Tbx1 is expressed in a pattern compatible with such a phenotype, immunohistochemistry and in situ hybridization analysis were performed. At E13.5, Tbx1 was detected in the body of hyoid bone (Supplementary Material, Fig. S8A ). At E14.5 and E16.5, Tbx1 was expressed in both the hyoid bone and the thyroid cartilage (Fig. 5Aa, b, d, e) , whereas the expression was not observed in Tbx1 OPKO mice at E14.5 (Fig. 5Bb) . At E18.5, Tbx1 expression was downregulated in these bone elements (Fig. 5Ac and f) . High Tbx1 expression was also seen in the proliferating and the pre-hypertrophic chondrocytes in the sternum at E18.5 ( Fig. 5Ag and h) . Interestingly, chondrocyte maturation occurs only after Tbx1 expression decreases in hyoid bone and sternum. As previously reported (33), Tbx1 expression was also observed in the neural crestderived Meckel's cartilage (Fig. 5Ca) , whereas the expression was not observed in Tbx1 NCKO mice at E16.5 (Fig. 5Cb) . These data demonstrated a requirement of Tbx1 for hyoid bone morphogenesis, chondrocyte maturation and subperiosteal bone formation.
Expression of Tbx1 in the developing calvarial bones
In cranial bone development, both cranial neural crest-and mesoderm-derived cells contribute to the morphogenesis. In a mouse, frontal bones are derived from neural crest and parietal bones are derived from mesoderm. The interparietal bone has a dual origin: the medial part is derived from the neural crest, 
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and the lateral part is derived from mesoderm (11). To address a possible role for Tbx1 in cranial bone development, we traced the fate of Tbx1-positive cells in calvarial primordium. We interbred Tbx1-Cre transgenic mice (5, 17, 34) , with R26R mice (25) . LacZ-positive regions were widely detected in head mesenchyme between E12.5 and E15.5 ( Fig. 5Da-d) and later in the parietal bones and the lateral part of interparietal bone at P1 (Fig. 5De) , suggesting that Tbx1 was expressed in the mesoderm-derived calvarial primordium. Histological analysis showed that Tbx1-progeny cells were mainly found in parietal and interparietal bones at E13.5 ( Fig. 5Eb-e) , whereas the frontal bones were excluded from LacZ expression (Fig. 5Ea) . We also examined localization of Tbx1 in the calvarial component prior to initiation of ossification. However, Tbx1 was hardly detected in the region of the parietal bone at E13.5 by in situ hybridization (Supplementary Material, Fig. S8B ), whereas Tbx1 expression in the tongue and surrounding oral epithelium was observed (8) . qPCR results also confirmed that Tbx1 was not expressed in calvarial osteoblasts from E13.5 and E16.5 embryos (Supplementary Material, Fig. S8C ). Since Tbx1 expression was detected in head mesenchyme at E9.5 (17), Tbx1 expression may be downregulated in the calvarial primordium before E13.5. Taken together, our linage analyses combined with the expression analysis suggest a potential role for Tbx1 at the early primordial stage of calvarial development.
Impaired osteogenesis in calvarial bones of Tbx1 2/2 mice
The phenotypic abnormalities noted in Tbx1 2/2 mice (Fig. 1) are reminiscent of those observed in CCD and Runx2 +/2 mutants (13, 15) . Given the expression of Tbx1 in the bone primordium and the abnormal bone formation in Tbx1 2/2 mice, we further speculated that defects in bone formation might result from downregulation of osteoblast-specific genes in the mutants. To address this possibility, we investigated the expression of osteoblast-specific genes in Tbx1 2/2 embryos and compared with that of wild-type controls. At E13.5, in situ hybridization showed that the Runx2 expression domain was significantly reduced in the parietal bones in the mutants (Fig. 6Ah) . The expression domain of bone sialoprotein (Bsp; Ibsp), an early marker of osteoblast differentiation, was also reduced in the parietal bones of Tbx1 2/2 embryos (Fig. 6Al) . Expression domains of Runx2 and Ibsp were moderately reduced in the frontal bones ( Fig. 6Af and j) . The expression of osteoblast-specific genes was also examined by whole-mount in situ hybridization at E16.5. Runx2 expression was observed in the edge of calvarial bones in both control and Tbx1 2/2 embryos, but the levels were reduced and calvarial bones were smaller in the mutant embryos ( Fig. 6Ba and b) . The expressions of Ibsp and osteocalcin (Bglap1/2), early and advanced osteoblast differentiation markers, respectively, extended into all calvarial membranous bones of wild-type embryos but their domains were considerably reduced in the Tbx1 2/2 embryos (Fig. 6Bc -h ). Since Tbx1 is not expressed in parietal mesenchymal progenitor cells later than E13.5 (Supplementary Material, Fig. S8B and C) , the interaction between Runx2 and Tbx1 may occur at an earlier stage.
The expression of Runx2 was also examined by whole-mount in situ hybridization at E13.5. Runx2 was expressed in the primordium of the neural crest-derived temporal bone in wild-type embryos, whereas no expression was observed in the mutants (Supplementary Material, Fig. S9A ). Consistent with Runx2 expression, the ossification center of the temporal bone was not observed in Tbx1 2/2 embryos at E15.5 (Supplementary Material, Fig. S9B ). Considering the fact that Tbx1 NCKO mice did not show the skeletal phenotype in temporal bones (Fig. 3) , Tbx1 in the non-neural crest mesoderm core affects Runx2 expression in the primordium of the temporal bone.
Tbx1 activates Runx2 expression in mesenchymal cells
The reduction in the Runx2 expression domain in calvaria (Fig. 6A and B) may be secondary to the reduction of the Runx2-positive primordial cell number, since Tbx1 was not expressed in the Runx2-expressing cells at E13.5 (Supplementary Material, Fig. S8B and C) . It is also possible that Tbx1 regulates Runx2 expression, since Tbx1 2/2 mice showed specific bone defects that recapitulate the skeletal phenotype of the Runx2 +/2 mice. To address this possibility, we examined the effect of Tbx1 on Runx2 expression in vitro using pluripotent C3H10T1/2 cells, infected with either adenovirus encoding Tbx1 or with control adenovirus encoding EGFP. Overexpression of Tbx1 resulted in a significant increase in the Runx2 expression compared with control cells (Fig. 6C) ; however, Tbx1 alone was insufficient to induce robust alkaline phosphatase activity observed in Runx2-expressing cells (Supplementary Material, Fig. S10B ). Overexpression of Tbx1 in rat osteoblast ROS 17/2.8 cells also induced endogenous Runx2 expression (Fig. 6D ), but not in COS1 cells (Supplementary Material, Fig. S10D ). Two evolutionarily conserved sequences resembling Tbx1-binding sites (TBEs) were identified in the Runx2 promoter (Supplementary Material,  Fig. S11A ). Promoter assays showed that Tbx1 could activate the Runx2 (22800/+111) promoter but failed to activate Runx2 (289/+111) promoter in either mesenchymal cell or osteoblastic cell lineage, despite the presence of two TBEs (Fig. 6E , and data not shown). As expected, introduction of mutations in the TBE1 or TBE2 did not affect Tbx1-mediated Runx2 activation (Supplementary Material, Fig. S11B ). Taken together, while Tbx1 alone was sufficient to induce Runx2 expression in pluripotent cells, this induction was likely to be mediated by outside of Runx2 (289/+111) promoter or by an indirect regulator of Runx2 expression.
DISCUSSION
The results presented here demonstrate that Tbx1 is one of the key regulators of early osteoblast differentiation and subsequent skeletal bone development. The following observations support Higher-magnification view of (b). pb, parietal bone; ip, interparietal bone; t, tongue; p, palatal shelf; oc, oral cavity; ey, eye. Scale bars: a, b, d, e, 400 mm; c, 100 mm.
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Human Molecular Genetics, 2015, Vol. 24, No. 2 this conclusion: (i) Tbx1 2/2 mice showed hypoplasia of subset of bones, strikingly similar to the phenotype of CCD patients and Runx2
+/2 mice, (ii) a cell-type specific deletion of Tbx1 in osteochondro-progenitor (Tbx1 OPKO ) or mesodermal (Tbx1 MKO ) lineages partially recapitulates the Tbx1 2/2 and Runx2 +/2 bone phenotypes, (iii) Tbx1 expression in neural crest cells of the second branchial arch is necessary for early morphogenesis and subsequent ossification in hyoid bone, (iv) Tbx1 is required for expression levels and domains of osteoblast differentiation genes (Runx2, Ibsp and Bglap) during bone development, and (v) Tbx1 induces Runx2 expression in vitro, suggesting that Tbx1 may activate bone formation through Runx2. CCD is typically an autosomal-dominant disorder and caused by heterozygous mutation in the RUNX2 gene (OMIM, #119600). However, Goodman et al. (35) reported a recessive inheritance of CCD (OMIM, #216330). In addition, four (4%) of CCD patients had a submucous cleft palate (36) . Since Tbx1 2/2 mice have submucous cleft palate (8) and have a similar bone phenotype to CCD, Tbx1 may be one of the candidate genes for a recessive form of CCD. 
Tbx1
2/2 mice have a skeletal bone phenotype
The Tbx1 2/2 mice show hypoplasia or aplasia of specific bones; however, a mechanism underlying the phenotype is different between each bone depending on the embryonic origin and surrounding tissues. First, we have established that Tbx1 expression in neural crest cells is necessary for the morphogenesis of the body of hyoid bone, where Tbx1 expression has not been reported previously. The absence of body of the hyoid bone and fusion to the thyroid cartilage might be a cause of the lack of milk and of their death. Deletion of Tbx1 in osteochondroprogenitor lineages or neural crest cells results in a similar hyoid phenotype, supporting the conclusion that Tbx1 regulates neural crest-derived osteochondro-progenitors during hyoid bone development. These results suggest that Tbx1 is not only involved in osteoblastic differentiation but also in early patterning. Interestingly, autopsied patients with 22q11.2 deletion syndrome showed an invisible hyoid ossification center (37) , or the delayed development of hyoid bone (38) .
Second, our results demonstrate that the abnormalities of other cranial neural crest-derived bones, such as temporal bones, mandibles and frontal bones, are secondary to defects in non-neural crest cells in the Tbx1 2/2 mice, which is consistent with the previous report (20) . It is likely that Tbx1 expression in the endodermal and mesodermal layers affects development of adjacent neural crest derivatives.
Third, our studies showed that Tbx1 is directly involved in mesoderm-derived calvarial bone development. Tbx1 was expressed in mesoderm-derived bone primordium and genetic deletion of Tbx1 in osteochondral progenitors or cranial mesoderm impaired development of Tbx1-progeny calvarial bone in mice. The mechanisms of the endochondral ossification also need to be further clarified, since Tbx1 mutants have bone abnormalities in xiphoid process, atlas, axis and basal skull. The synchondroses in the Tbx1 2/2 basal skull were completely ossified (6, 8, 17) , whereas such phenotype was not reported in either Runx2 +/2 or Runx2 2/2 mice (13,15). Tbx1 2/2 mice did not show significant phenotypes in long bones; however, wholemount in situ analysis showed that Tbx1 was expressed in the perichondrium in the limbs at E13.5 (N.F., unpublished data).
Tbx1 regulates osteoblastic differentiation during bone development
The present study demonstrates a novel and important requirement for Tbx1 in regulating calvarial osteogenesis. Consistent with a hypoplasia of membranous bones in Tbx1 2/2 embryos, our in situ hybridization results showed that Runx2 expression domain is reduced in the calvarial bones in the absence of Tbx1. Since Runx2 is necessary for potentiating the osteogenic fate of the osteochondro-progenitors, its compromised expression may account for the delayed calvarial ossification in Tbx1 2/2 mice. Furthermore, ablation of Tbx1 results in the decreased expression of Ibsp and Bglap, which expression is dependent on Runx2 (39), suggesting that Tbx1 also lies upstream of osteoblastic genes during early phase of calvarial osteogenesis, thereby regulating osteoblast differentiation. Consistently, loss of Tbx1 affected Runx2 expression in vivo and overexpression of Tbx1 induced endogenous Runx2 expression in vitro. However, analysis of the promoter region of the Runx2 gene revealed that whereas Tbx1 moderately activates Runx2 (22800/+111) promoter, it did not activate the Runx2 (289/+111) promoter, which contained two evolutionarily conserved TBEs. Since developmental genes are known to rely on enhancers far from their promoter, sometimes inside or beyond unrelated adjacent genes (40), Tbx1 may regulate distant enhancers of the Runx2 gene, or may be an indirect regulator of the Runx2 gene. It is also possible that Tbx1 is involved in the maintenance of cell population expressing Runx2 during the bone development.
The impaired intramembranous ossification resulting from the deletion of Tbx1 is similar to that of Runx2 +/2 mice; however, the phenotype of Runx2 +/2 and Tbx1 2/2 mice differs in hyoid bone. Tbx1 2/2 mice showed a complete absence of ossification of hyoid bone, whereas only hypoplastic hyoid bone was observed in Runx2 +/2 mice (15). We postulate that this difference may be due to a primary role of Tbx1 in early patterning and perichondrial ossification in hyoid bone. During the bone development, bone collar formation occurs secondary to chondrocyte hypertrophy (24, 41) ; therefore, we speculate that collar formation may be compromised in the hyoid bone of Tbx1 mutant, where chondrocyte hypertrophy failed to take place.
Taken together, our results indicate that, in addition to its role in early morphogenetic and osteogenic commitment in hyoid bone, Tbx1 is required for mediating mesoderm-derived osteogenesis, especially at the early stage of primordium growth and osteoblast differentiation. Additional studies further elucidating how Tbx1 involves in chondrogenesis in the basal skull synchondrosis may also explain the molecular mechanism for the endochondral ossification. 
MATERIALS AND METHODS
Mouse mutants
Cartilage and bone staining
Skeletal preparations were stained using alcian blue and alizarin red, respectively, as described previously (8) .
Histology and immunohistochemistry
Embryos or tissue samples were prepared as previously described (44) . Paraffin-embedded sections were stained with hematoxylin and eosin (H&E) for routine histology, with Safranin O/hematoxylin/ fast green for cartilage. Immunohistochemistry was
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Human Molecular Genetics, 2015, Vol. 24, No. 2 performed as previously described (44), using rabbit anti-Tbx1 (34-9800, 1:100, Invitrogen Life Technologies, Grand Island, NY, USA).
b-Galactosidase staining b-Galactosidase staining was performed as previously described (8) . For whole-mount b-galactosidase staining, E16.5 and P1 mice were skinned before fixation.
In situ hybridization
Embryos were harvested at E13.5, or E16.5 and fixed in 4% paraformaldehyde overnight at 4 8C. E16.5 embryos for wholemount in situ hybridization of calvaria were skinned before fixation. Whole-mount in situ hybridization was performed using digoxigenin-labeled riboprobes for Runx2 (45) ′ . Riboprobes for section in situ hybridization were labeled with 35 S-UTP (Amersham, GE Healthcare, Piscateway, NJ, USA) using the MAXIscript in vitro transcription kit (Ambion, Life Technologies) as previously described (46) . Images were captured using ZEISS AXIO Imager.A1 and analysis software (AxioVision). Signals shown in red were pseudocolored by processing Photoshop CS5.1.
Adenovirus transfection
C3H10T1/2 cells (RIKEN) were grown in Dulbecco's minimal Essential medium (DMEM), supplemented with 10% fetal bovine serum (FBS). Adenoviruses for Tbx1 and EGFP were described previously (8) . Recombinant adenovirus for Runx2 was newly generated using the ViraPower TM adenoviral expression system (Invitrogen Life Technologies). Briefly, the cells were seeded into 24-well culture plates at a density of 2 × 10 5 cells per well. Using the pAd-CMV adenovirus construct, Tbx1, Runx2 and control EGFP transfection were performed at 400 or 500 multiplicity of infection. For viral infection, cells were treated with virus in antibiotic-and serum-free a-minimal essential medium (a-MEM) overnight, and then complete a-MEM medium, supplemented with 10% FBS and penicillin streptomycin, was added to the cells.
Real-time quantitative PCR (qPCR)
Total RNA was extracted from C3H10T1/2 cells (n ¼ 3 per sample) using TRIzol reagent (Invitrogen) without pooling the samples. cDNA was synthesized using the First-Strand cDNA Synthesis Kit for RT-PCR (AMV) (Roche Applied Science, Indianapolis, IN, USA). qPCR was performed with LightCycler using the LightCycler FastStart DNA MasterPLUS SYBR Green I kit (Roche) according to the manufacturer's instructions. The b-actin (ActB) mRNA level was used for normalization. Primer sequences are described in Supplementary Material. qPCR assays were performed in three independent experiments in triplicate.
Promoter assay COS1 cells (RIKEN) were grown in DMEM, supplemented with 10% FBS. FuGENE6 (Roche) was used for transient transfections according to the manufacturer's instructions. Expression vector for Tbx1 was cloned into a modified pcDNA3.1 vector containing an N-terminal Myc-epitope tag, respectively. pGL2-Runx2 reporter plasmids were described previously (45, 47) . Reporter plasmids (150 ng) and indicated amounts of expression plasmids were transfected with 100 ng of a pCMVb-galactosidase expression plasmid to monitor transfection efficiency. Cell extracts were prepared 48 h after transfection and assayed for luciferase activity (Promega, Madison, WI, USA). Promoter assays were performed in three independent experiments, each performed in duplicates.
Western blotting ROS 17/2.8 cells were maintained in a-MEM containing 10% FBS. For stable transfections, ROS 17/2.8 cells were selected using 400 mg/ml G418 and individual clones were harvested and amplified prior to analysis, as described previously (48) . Cell lysates were harvested as previously described (48) . Lysates were subjected to SDS -PAGE. Blots were immunolabeled with rabbit anti-Myc (A-14; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-Runx2 (M-70; Santa Cruz), mouse anti-a-tubulin (B-7; Santa Cruz) or mouse anti-b-tubulin (H-235; Santa Cruz) followed by secondary labeling with goat anti-rabbit or rabbit anti-mouse HRP-conjugated antibodies (Bio-Rad, Hercules, CA, USA) and proteins were visualized with a chemiluminescence detection system (Santa Cruz).
Statistical analysis
The experimental data were analyzed by two-tailed Student's t-test and expressed as means + SEM. A P-value ,0.05 was considered to be significant.
